top of page
Search

Pain Management: Opioid Conversion — Criteria & Principles for MRCP Part 1

TL;DR

Opioid conversion is a high-yield safety topic in MRCP Part 1, testing principles rather than complex calculations. You must understand relative opioid potency, incomplete cross-tolerance, route changes, and toxicity, especially in older adults and renal impairment. Mastering these rules helps you avoid common exam traps and mirrors safe real-world prescribing.


Why opioid conversion matters in MRCP Part 1

Pain management questions in MRCP Part 1 frequently assess whether candidates can prescribe opioids safely rather than whether they can memorise dose tables. Errors in opioid conversion are a well-recognised cause of morbidity and mortality, which is why examiners focus on principles, judgement, and risk recognition.

Typical exam scenarios include:

  • Switching opioids in cancer or palliative care

  • Patients with renal or hepatic impairment

  • Elderly patients with delirium or drowsiness

  • Route changes (oral to transdermal or parenteral)

If you approach these questions with arithmetic alone, you will lose marks.


Scope of opioid conversion for MRCP Part 1

You are not expected to perform detailed equianalgesic calculations. Instead, the exam tests whether you can:

  • Compare relative opioid strength

  • Apply dose reduction when switching

  • Recognise opioid toxicity

  • Choose safer opioids in renal failure

Think like a clinician, not a calculator.

For a broader syllabus overview, see the official MRCP(UK) guidance:https://www.mrcpuk.org/mrcpuk-examinations/part-1


Core principles of opioid conversion (high-yield)

1. Morphine is the reference standard

Most opioid comparisons use oral morphine as the benchmark. Other opioids are judged relative to it.

2. Route changes increase risk

Changing the route of administration often has more impact than changing the drug itself. Oral, intravenous, and transdermal opioids have very different bioavailability.

3. Incomplete cross-tolerance always applies

When switching from one opioid to another, reduce the calculated equianalgesic dose by 25–50%.

This single rule is one of the most frequently tested facts in MRCP Part 1.

4. Transdermal opioids are not for opioid-naïve patients

Fentanyl and buprenorphine patches:

  • Are suitable only for stable, chronic pain

  • Take 12–24 hours to reach steady state

  • Continue to release drug after removal

Using them in opioid-naïve patients is unsafe and commonly tested as a wrong option.

5. Methadone is unpredictable

Methadone has:

  • A long and variable half-life

  • Non-linear conversion ratios

For MRCP Part 1, methadone is rarely the correct answer unless the question explicitly focuses on specialist pain management.

6. Renal impairment changes opioid choice

Morphine’s active metabolites accumulate in renal failure, causing:

  • Confusion

  • Hallucinations

  • Myoclonus

Fentanyl and buprenorphine are safer options and frequently tested alternatives.

BNF reference (opioids in renal impairment):https://bnf.nice.org.uk/treatment-summary/analgesics/

7. Breakthrough pain dosing

Breakthrough analgesia is typically:

  • One-sixth of the total daily opioid dose

  • Short-acting

  • Prescribed “as required”

Never confuse breakthrough dosing with background opioid conversion.

8. Elderly patients need lower doses

Older adults have reduced drug clearance and increased CNS sensitivity. In exams, choose:

  • Lower starting doses

  • Slower titration

9. Sedation precedes respiratory depression

Early opioid toxicity presents with:

  • Drowsiness

  • Confusion

  • Pinpoint pupils

Respiratory depression is a late sign, not an early one.

10. Naloxone is not for mild toxicity

Naloxone is reserved for life-threatening respiratory depression. Using it for mild sedation is incorrect and may precipitate severe pain and withdrawal.


MRCP Part 1 candidate revising pain management and opioid pharmacology

Simple equianalgesic comparison (exam-level)

Oral opioid

Approximate potency vs oral morphine

Codeine

~1/10

Tramadol

~1/5

Oxycodone

~1.5 × morphine

Hydromorphone

~5 × morphine

In MRCP Part 1, you are expected to recognise relative strength, not calculate exact doses.

Five most tested subtopics

  1. Switching oral morphine to transdermal fentanyl

  2. Opioid toxicity in renal failure

  3. Incomplete cross-tolerance dose reduction

  4. Breakthrough analgesia principles

  5. Opioid prescribing in older adults


Mini-case (exam style)

Question A 74-year-old man with metastatic prostate cancer is taking oral morphine for chronic pain. He develops confusion and vivid dreams. His eGFR is 22 mL/min. What is the most appropriate next step?

Answer Switch to fentanyl at a reduced equivalent dose.

Explanation Morphine metabolites accumulate in renal failure, causing neurotoxicity. Fentanyl has no active metabolites and is safer. Dose reduction accounts for incomplete cross-tolerance and advanced age.


Common pitfalls (exam traps)

  • Forgetting dose reduction when switching opioids

  • Prescribing fentanyl patches to opioid-naïve patients

  • Ignoring renal function when choosing morphine

  • Treating mild sedation with naloxone

  • Assuming conversion ratios are exact and linear


Practical study checklist

  • Learn relative opioid strength, not dose tables

  • Always apply 25–50% dose reduction when switching

  • Think renal function before prescribing morphine

  • Recognise early opioid toxicity

  • Practise questions under exam conditions

You can reinforce these principles using MRCP-style questions here:https://crackmedicine.com/qbank/

For exam simulation, attempt a full paper:https://crackmedicine.com/mock-tests/


Frequently asked questions

Do I need to memorise opioid conversion tables for MRCP Part 1?

No. The exam focuses on principles of safety, relative potency, and recognising inappropriate choices.

Why is dose reduction required when switching opioids?

Because incomplete cross-tolerance increases sensitivity to the new opioid, raising toxicity risk.

Which opioid is safest in renal failure for exams?

Fentanyl or buprenorphine, as they lack active metabolites.

Are fentanyl patches suitable for acute pain?

No. They are only appropriate for stable, chronic pain in opioid-tolerant patients.


Ready to start?

Opioid conversion questions reward clinical judgement, not mathematical precision. If you anchor your answers around safety, patient factors, and pharmacology, you will consistently pick the correct option in MRCP Part 1.

For a structured revision pathway, start with the MRCP Part 1 hub:https://crackmedicine.com/mrcp-part-1/


Sources

 
 
 

Comments

bottom of page